FDA to review uniQure's Huntington's gene therapy, decision due on May 2027 | Reuters

FDA sets May 2027 review date for uniQure's Huntington's gene therapy

The FDA will review uniQure's gene therapy for Huntington's disease, with a decision expected in May 2027. The agency has also scheduled an advisory committee meeting.